Valve assembly for a medicament delivery device

Abstract

To provide a valve assembly including a valve sleeve that ensures that a cannula and a flow path of a system remain uncontaminated during operation of the system.SOLUTION: A valve assembly for a drug delivery device includes a valve housing, a cannula, a valve boot coupled to the valve housing and defining an interior space, a valve sleeve defining a cannula space and configured to move from a pre-use position in which a first end of the cannula is received within the cannula space to a use position in which the first end of the cannula extends outside of the valve sleeve and the cannula space, and a piercing member having a body with a piercing tip. The valve sleeve includes a first cylindrical portion having a convex tip, a second portion extending from the first cylindrical portion, and a third frustoconical portion extending from the second portion.SELECTED DRAWING: Figure 17

Description

[Technical Field]

[0001] The present invention relates to a valve assembly for a medication delivery device. [Background technology]

[0002] This application claims priority to U.S. Provisional Application Serial No. 63 / 054,850, filed July 22, 2020.

[0003] Various types of automatic injection or drug delivery devices have been developed to allow medications and other liquid therapeutic formulations to be administered or self-injected by untrained personnel. These devices generally include a reservoir prefilled with the liquid therapeutic formulation and some type of automatic needle injection mechanism that can be triggered by the user. When the volume of the liquid or medication to be administered is generally less than a certain volume, such as 1 mL, an automatic injector device is typically used, which typically has an injection time of approximately 10 to 15 seconds. When the volume of the liquid or medication to be administered exceeds 1 mL, the injection time generally becomes longer, resulting in difficulty for the patient in maintaining contact between the device and the target area of ​​the patient's skin. Furthermore, as the volume of medication to be administered increases, an increased time period for injection becomes desirable. The conventional method for slowly injecting medication into a patient is to start an IV and slowly inject the medication into the patient's body. Such procedures are typically performed in a hospital or outpatient setting.

[0004] Certain devices allow for self-injection in a home setting and can gradually inject a liquid therapeutic formulation into a patient's skin. In some cases, these devices are small enough (both in height and overall size) to allow them to be "worn" by the patient while the liquid therapeutic formulation is being injected into the patient. These devices typically include a pump or other type of discharge mechanism for causing the liquid therapeutic formulation to flow from a reservoir into the injection needle. Such devices also typically include a valve or flow control mechanism for initiating the flow of the liquid therapeutic formulation at the appropriate time, and a trigger mechanism for initiating the injection. Summary of the Invention [Problem to be solved by the invention]

[0005] A valve assembly is provided that includes a valve sleeve that ensures that the cannula and the system flow path remain uncontaminated during operation of the system. [Means for solving the problem]

[0006] In one aspect or embodiment, a valve assembly for a drug delivery device includes: a valve housing having a first side and a second side opposite the first side; a cannula having a first end and a second end opposite the first end, the cannula defining a central passage; a valve boot connected to the valve housing and defining an interior space, the valve boot configured to move from a pre-use position in which the first end of the cannula is received within the interior space to a use position in which the first end of the cannula extends outside the valve boot and the interior space; a valve sleeve defining the cannula space, the valve sleeve configured to move from a pre-use position in which the first end of the cannula is received within the cannula space to a use position in which the first end of the cannula extends outside the valve sleeve and the cannula space; and a piercing member having a body with a piercing tip. The body of the piercing member has a first end and a second end disposed opposite the first end, and the piercing member is engaged with the valve sleeve.

[0007] The piercing member may be completely spaced from the valve boot. The second end of the piercing member body may be engaged with the valve sleeve. The second end of the piercing member body may be received by a recessed area defined by the valve sleeve.

[0008] The valve sleeve may include a first cylindrical portion having a convex tip, a second portion extending from the first cylindrical portion, and a third full-conical portion extending from the second portion. The second end of the piercing member body may be received in a concave area defined by the second portion of the valve sleeve. The first cylindrical portion of the valve sleeve may be disposed between the first end of the piercing member body and the second end of the piercing member body. The piercing member body may be cylindrical.

[0009] The body of the piercing member may define a central passageway that receives a portion of the valve sleeve. The valve sleeve may be molded from an elastomeric material. The second portion of the valve sleeve may include a full conical portion and a cylindrical portion. The third full conical portion of the valve sleeve may include at least one concave portion configured to facilitate collapse and deformation of the valve sleeve. The valve boot may be molded from an elastomeric material. The piercing member may be molded from a metal.

[0010] In a further aspect or embodiment, a medication delivery device includes a housing; a cartridge received within the housing, the cartridge configured to receive a medication; a drive assembly received within the housing, the drive assembly configured to engage the cartridge and dispense the medication from the cartridge; a needle actuator assembly received within the housing, the needle actuator assembly including a patient needle configured to pierce the skin of a patient; and a valve assembly as described in any of the aspects or embodiments described above. [Brief explanation of the drawings]

[0011] The above and other features and advantages of the present disclosure, and the manner in which they are achieved, will become more apparent, and the disclosure itself will be better understood, by reference to the following description of embodiments of the disclosure taken in conjunction with the accompanying drawings.

[0012] [Figure 1] FIG. 1 is a perspective view of a drug delivery system according to one aspect or embodiment of the present application. [Figure 2] FIG. 2 is a perspective cross-sectional view of the drug delivery system of FIG. [Figure 3] FIG. 3 is a cross-sectional front view of the drug delivery system of FIG. [Figure 4]FIG. 4 is a top view of the drug delivery system of FIG. 1 with the top of the housing removed, showing the drug delivery system in a pre-use position. [Figure 5] FIG. 5 is a top cross-sectional view of the drug delivery system of FIG. 1, showing the drug delivery system in a pre-use position. [Figure 6] FIG. 6 is a front cross-sectional view of the drug delivery system of FIG. 1, showing the drug delivery system in a pre-use position. [Figure 7] FIG. 7 is a top view of the drug delivery system of FIG. 1 with the top of the housing removed, showing the drug delivery system in an initial operating position. [Figure 8] FIG. 8 is a top cross-sectional view of the drug delivery system of FIG. 1, showing the drug delivery system in an initial actuated position. [Figure 9] FIG. 9 is a front cross-sectional view of the drug delivery system of FIG. 1, showing the drug delivery system in an initial actuated position. [Figure 10] FIG. 10 is a top view of the drug delivery system of FIG. 1 with the top of the housing removed, showing the drug delivery system in the use position. [Figure 11] FIG. 11 is a top cross-sectional view of the drug delivery system of FIG. 1, showing the drug delivery system in the position for use. [Figure 12] FIG. 12 is a cross-sectional front view of the drug delivery system of FIG. 1, showing the drug delivery system in the position for use. [Figure 13] FIG. 13 is a top view of the drug delivery system of FIG. 1 with the top of the housing removed to show the drug delivery system in a post-use position. [Figure 14] FIG. 14 is a top cross-sectional view of the drug delivery system of FIG. 1, showing the drug delivery system in a post-use position. [Figure 15A] FIG. 15A is a front cross-sectional view of the drug delivery system of FIG. 1, showing the drug delivery system in a post-use position. [Figure 15B]FIG. 15B is a front cross-sectional view of the drug delivery system of FIG. 1 showing the pad of the drug delivery system in a pre-use position. [Figure 15C] FIG. 15C is a perspective cross-sectional view of the drug delivery system of FIG. 1, showing the pad of the drug delivery system in a pre-use position. [Figure 15D] FIG. 15D is a perspective cross-sectional view of the drug delivery system of FIG. 1 showing the pad of the drug delivery system in a pre-use position. [Figure 16] FIG. 16 is a partial cross-sectional view of the drug delivery system of FIG. 1 showing the valve assembly. [Figure 17] 17 is a cross-sectional view of a valve assembly of the drug delivery system of FIG. [Figure 18] 18 is a perspective view of a valve sleeve of the valve assembly of the drug delivery system of FIG. 1. FIG. [Figure 19] 19 is a perspective view of a piercing member of the valve assembly of the drug delivery system of FIG. 1. FIG. DETAILED DESCRIPTION OF THE INVENTION

[0013] The following description is provided to enable any person skilled in the art to make and use the described embodiments as contemplated for practicing the invention. However, various modifications, equivalents, variations, and alternatives will remain readily apparent to those skilled in the art. Any and all such modifications, variations, equivalents, and alternatives are intended to be within the spirit and scope of the present invention.

[0014] Hereinafter, for purposes of description, the terms "upper," "lower," "right," "left," "vertical," "horizontal," "top," "bottom," "transverse," "longitudinal," and their derivatives shall refer to the present invention as oriented in the drawings. However, it should be understood that the present invention may assume various alternative modifications unless expressly specified to the contrary. It should also be understood that the specific devices illustrated in the accompanying drawings and described in the following specification are merely exemplary embodiments of the present invention. Hence, specific dimensions and other physical characteristics related to the embodiments disclosed herein are not to be considered limiting.

[0015] 1-16 , a drug delivery system 10 includes a drive assembly 12, a reservoir 14, a valve assembly 16, and a needle actuator assembly 18. The drive assembly 12, the reservoir 14, the valve assembly 16, and the needle actuator assembly 18 are at least partially disposed within a housing 20. The housing 20 includes a top portion 22 and a bottom portion 24, although other suitable arrangements for the housing 20 may be utilized. In one embodiment, the drug delivery system 10 is a syringe device that is attached to or secured to a user and configured to deliver a predetermined dose of a drug provided within the reservoir 14 via injection into the user. The system 10 may be utilized to perform a "bolus injection," in which the drug is delivered within a set time period. The drug may be delivered over a time period up to 45 minutes, although other suitable injection volumes and durations may be utilized. The bolus administration or delivery may be performed using a rate limiting factor or may not have a specific rate limiting factor. The system 10 may deliver the drug to the user at a fixed pressure with a variable rate. The general operation of system 10 is described below with reference to FIGS.

[0016] 1-16 , system 10 is configured to function through engagement of actuator button 26 by a user, whereby needle 28 of needle assembly 18 pierces the user's skin, resulting in actuation of drive assembly 12, placing needle 28 in fluid communication with container 14, expelling fluid or medicament from container 14, and completing withdrawal of needle 28 following medicament injection. The general operation of the drug delivery system is shown and described in International Publication Nos. 2013 / 155153 and 2014 / 179774, which are incorporated herein by reference in their entireties. The operation of system 10 is also shown and described in U.S. Publication No. 2017 / 0354788, which is incorporated herein by reference in its entirety. Housing 20 of system 10 includes an indicator window 30 for viewing indicator arrangement 32 configured to provide an indication to the user regarding the status of system 10, and a container window 31 for viewing container 14. The indicator window 30 may be a magnifying lens to provide a clearer view of the indicator arrangement 32. The indicator arrangement 32 moves along the needle actuator assembly 18 during use of the system 10 to indicate the pre-use, use, and post-use states of the system 10. The indicator arrangement 32 provides a visual indication of the state, although other suitable indications, such as audible or tactile, may be provided as alternative or additional indications.

[0017] 4-6 , during the pre-use position of system 10, container 14 is spaced apart from drive assembly 12, and valve assembly 16 and needle 28 are in the retracted position. During initial actuation of system 10, as shown in FIGS. 7-9 , drive assembly 12 engages container 14 to move container 14 toward valve assembly 16, which is configured to penetrate closure 36 of container 14 and place medicament within container 14 in fluid communication with needle 28 via tubing (not shown) or other suitable arrangement. Drive assembly 12 is configured to engage stopper 34 of container 14, which will initially move the entire container 14 into engagement with valve assembly 16 due to the incompressibility of the fluid or medicament within container 14. Initial actuation of system 10 is triggered by engagement of actuator button 26 by a user, which releases needle actuator assembly 18 and drive assembly 12, as described in further detail below. During initial actuation, needle 28 is still in the retracted position and is about to move to the extended position for injecting the user of system 10 .

[0018] During the use position of system 10, as shown in FIGS. 10-12, needle 28 is in an extended position at least partially outside housing 20, and drive assembly 12 moves stopper 34 within container 14 to deliver medicament from container 14 to a user through needle 28. In the use position, valve assembly 16 has already pierced closure 36 of container 14 to place needle 28 in fluid communication with container 14, which also allows drive assembly 12 to move stopper 34 relative to container 14 so that fluid can be dispensed from container 14. In the post-use position of system 10, as shown in FIGS. 13-15, needle 28 is in a retracted position and is engaged with pad 38 to seal needle 28 and prevent any residual flow of fluid or medicament from container 14.

[0019] 16-19 , as described above, the valve assembly 16 operates to facilitate fluid communication between the container 14 and the needle actuator assembly 18. The valve assembly 16 includes a valve housing 52, a cannula 54, a piercing member 56, and a valve boot 58. The valve assembly 16 also includes a valve sleeve 60. The valve housing 52 has a first side 62 and a second side 64 opposite the first side 62. The valve housing 52 may be formed integrally with the housing 20 of the system 10 or may be formed as a separate component. The cannula 54 has a first end 66 and a second end 68 opposite the first end 66. The cannula 54 defines a central passage 70. The first end 66 of the cannula 54 is sharp and configured to pierce a septum of the container 14. A second end 68 of the cannula 54 is received by and secured to the valve housing 52. The valve housing 52 is in fluid communication with the needle actuator assembly 18 via tubing (not shown) to provide a fluid flow path from the cannula 54 to the needle actuator assembly 18.

[0020] 16-19 , the piercing member 56 includes a body 72 with a piercing tip 74 extending therefrom. The body 72 of the piercing member 56 has a first end 76 and a second end 78 disposed opposite the first end 76. The piercing tip 74 extends from the first end 76 of the body 72. The piercing member 56 is engaged with the valve sleeve 60. The piercing member 56 is completely spaced apart from the valve boot 58. In one aspect or embodiment, the piercing member 56 does not contact the valve boot 58, either directly or indirectly. The second end 78 of the body 72 of the piercing member 56 is engaged with the valve sleeve 60. In one aspect or embodiment, the second end 78 of the body 72 is received by a recessed area 80 defined by the valve sleeve 60. The body 72 of the piercing member 56 is cylindrical, although other suitable shapes and configurations may be utilized. The body 72 of the piercing member 56 defines a central passage 82 and receives a portion of the valve sleeve 60. In one aspect or embodiment, the piercing member 56 is flush disposed over the valve sleeve 60, with the piercing member 56 contacting the valve sleeve 60 from the first end 76 of the body 72 to the second end 78 of the body 72. The piercing member 56 is formed from metal, although other suitable materials may be utilized. The piercing member 56 may be manufactured using stamping, rolling, and / or forming processes.

[0021] The valve boot 58 is coupled to the valve housing 52 and defines an interior space 84. The valve boot 58 may be molded from an elastomeric material, although other suitable materials or combinations of materials may be utilized. The valve boot 58 is configured to move from a pre-use position in which the first end 66 of the cannula 54 and the piercing tip 74 of the piercing member 56 are received within the interior space 84 to a use position in which the piercing tip 74 of the piercing member 56 and the first end 66 of the cannula 54 extend outside the valve boot 58 and the interior space 84. The pre-use position of the valve boot 58 and the valve assembly 16 is shown in FIG. 17. The use position of the valve boot 58 and the valve assembly 16 is shown in FIG. 16. In the use position, the piercing tip 74 pierces the valve boot 58 and the foil seal (not shown) on the container 14, and the cannula 54 pierces the septum of the container 14 to provide fluid communication between the interior of the container 14 and the piercing member 56 moving toward the valve housing 52.

[0022] 16-18 , the valve sleeve 60 is disposed within the interior space 84 defined by the valve boot 58. The valve sleeve 60 defines a cannula space 86 and is configured to move from a pre-use position in which the first end 66 of the cannula 54 is received within the cannula space 86 to a use position in which the first end 66 of the cannula 54 extends outside the valve sleeve 60 and the cannula space 86. The valve sleeve 60 may be molded from an elastomeric material, such as a rubber material, although other suitable materials or combinations of materials may also be utilized. The valve sleeve 60 includes a first cylindrical portion 88 having a convex tip 90, a second portion 92 extending from the first cylindrical portion 88, and a third fulcrum-conical portion 94 extending from the second portion 92. The second portion 92 is fulcrum-conical and cylindrical. The third full conical portion 94 of the valve sleeve 60 may include one or more recessed portions 96 to facilitate collapse and deformation of the valve sleeve 60. When the valve assembly 16 engages the container 14, the valve sleeve 60 will contract as the first end 66 of the cannula 54 extends through the valve sleeve 60.

[0023] The valve sleeve 60 is configured to ensure that the cannula 54 and the flow path of the system 10 remain uncontaminated during operation of the system 10. During operation of the system 10, as described above, the container 14 is moved into engagement with the valve boot 58, collapsing the valve boot 58 so that the piercing tip 74 of the piercing member 56 pierces the foil seal of the container 14 and the valve boot 58, forming respective chads or flaps (not shown). The valve sleeve 60 prevents any contaminants present on the container 14 and the valve boot 58 from being ejected or thrown from the container 14 or the valve boot 58 onto or into the cannula 54. The valve sleeve 60 also protects the cannula 54 from contact with the chad or flaps formed by the piercing member 76 and minimizes the surface area of ​​the closure 36 of the container 14 through which the cannula 54 must pass. Valve sleeve 60 is also configured to prevent the settling of entrained contaminants on the exterior and interior surfaces of cannula 54, thereby preventing contamination caused by decompression of valve boot 58 when valve boot 58 is compressed and subsequently pierced by piercing member 76.

[0024] In one aspect or embodiment, the second end 78 of the body 72 of the piercing member 56 may be flared to allow the piercing member 56 to more easily slide over the first cylindrical portion 88 of the valve sleeve 60.

[0025] In one aspect or embodiment, the thickness of the valve sleeve 60 and the angles of the first cylindrical portion 88, second portion 92, and third full-conical portion 94 may be varied to optimize the force required to move the valve sleeve from the pre-use position to the use position. The valve sleeve 60 may be configured to fully penetrate the valve boot 58 before the valve sleeve 60 collapses or moves from the pre-use position to the use position, as described above.

[0026] 17 , the second end 78 of the body 72 of the piercing member 56 is received in the recessed area 80 defined by the second portion 92 of the valve sleeve 60. The first cylindrical portion 88 of the valve sleeve 60 is disposed between the first end 76 of the body 72 of the piercing member 56 and the second end 78 of the body 72 of the piercing member 56.

[0027] Elements of one disclosed embodiment can be combined with elements of one or more other disclosed embodiments to form different combinations, all of which are contemplated within the scope of the present invention.

[0028] While this disclosure has been described as having an exemplary design, the disclosure can be further modified within the spirit and scope of the disclosure. Accordingly, this application is intended to cover any variations, uses, or adaptations of the disclosure using its general principles. Further, this application is intended to cover such departures from the disclosure as come within known or customary practice in the art to which this disclosure pertains and fall within the scope of the appended claims.

Claims

1. 1. A valve assembly for a medication delivery device, comprising: a valve housing having a first side and a second side disposed opposite the first side; a cannula having a first end and a second end disposed opposite the first end, the cannula defining a central passage; a valve boot connected to the valve housing and defining an interior space, the valve boot configured to move from a pre-use position in which the first end of the cannula is received within the interior space to a use position in which the first end of the cannula extends outside the valve boot and the interior space; a valve sleeve defining a cannula space, the valve sleeve configured to move from a pre-use position in which the first end of the cannula is received within the cannula space to a use position in which the first end of the cannula extends outside the valve sleeve and the cannula space; a piercing member having a body with a piercing tip, the body having a first end and a second end opposite the first end, the piercing member engaged with the valve sleeve; Equipped with The valve assembly, wherein the valve sleeve comprises a first cylindrical portion having a convex tip, a second portion extending from the first cylindrical portion, and a third fulcrum conical portion extending from the second portion.

2. The valve assembly of claim 1 , wherein the piercing member is completely spaced from the valve boot.

3. The valve assembly of claim 1 , wherein the second end of the body of the piercing member is engaged with the valve sleeve.

4. The valve assembly of claim 3 , wherein the second end of the body of the piercing member is received in a recessed area defined by the valve sleeve.

5. The valve assembly of claim 1 , wherein the second end of the body of the piercing member is received by a recessed area defined by the second portion of the valve sleeve.

6. 2. The valve assembly of claim 1, wherein the first cylindrical portion of the valve sleeve is disposed between the first end and the second end of the body of the piercing member.

7. The valve assembly of claim 1 , wherein the second portion of the valve sleeve includes a full conical portion and a cylindrical portion.

8. 2. The valve assembly of claim 1, wherein the third full conical portion of the valve sleeve includes at least one concave portion configured to facilitate collapse and deformation of the valve sleeve.

9. The valve assembly of claim 1 , wherein the body of the piercing member is cylindrical.

10. The valve assembly of claim 1 , wherein the body of the piercing member defines a central passageway, the central passageway receiving a portion of the valve sleeve.

11. The valve assembly of claim 1 , wherein the valve sleeve comprises an elastomeric material.

12. The valve assembly of claim 1 , wherein the valve boot comprises an elastomeric material.

13. The valve assembly of claim 1 , wherein the piercing member comprises a metal.

14. Housing and a cartridge received within the housing, the cartridge configured to receive a medicament; a drive assembly received within the housing and configured to engage the cartridge to dispense medicament from the cartridge; a needle actuator assembly received within the housing, the needle actuator assembly including a patient needle configured to pierce the skin of a patient; 1. A valve assembly comprising: a valve housing having a first side and a second side disposed opposite the first side; a cannula having a first end and a second end disposed opposite the first end, the cannula defining a central passage; a valve boot connected to the valve housing and defining an interior space, the valve boot configured to move from a pre-use position in which the first end of the cannula is received within the interior space to a use position in which the first end of the cannula extends outside the valve boot and the interior space; a valve sleeve defining a cannula space, the valve sleeve configured to move from a pre-use position in which the first end of the cannula is received within the cannula space to a use position in which the first end of the cannula extends outside the valve sleeve and the cannula space; the valve assembly including a piercing member having a body with a piercing tip, the body having a first end and a second end disposed opposite the first end, the piercing member being engaged with the valve sleeve; Equipped with A medication delivery device, wherein the valve sleeve comprises a first cylindrical portion having a convex tip, a second portion extending from the first cylindrical portion, and a third fulcrum conical portion extending from the second portion.

Images